Novel Combinatorial MicroRNA-Binding Sites in AAV Vectors Synergistically Diminish Antigen Presentation and Transgene Immunity for Efficient and Stable Transduction
Authors:
Open Access
- 28 April 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12
Abstract
Recombinant adeno-associated virus (rAAV) platforms hold promise for in vivo gene therapy but are undermined by the undesirable transduction of antigen presenting cells (APCs), which in turn can trigger host immunity towards rAAV-expressed transgene products. In light of recent adverse events in patients receiving high systemic AAV vector doses that were speculated to be related to host immune responses, development of strategies to mute innate and adaptive immunity is imperative. The use of miRNA binding sites (miR-BSs) to confer endogenous miRNA-mediated regulation to detarget transgene expression from APCs has shown promise for reducing transgene immunity. Studies have shown that designing miR-142BSs into rAAV1 vectors were able to repress costimulatory signals in dendritic cells (DCs), blunt the cytotoxic T cell response, and attenuate clearance of transduced muscle cells in mice to allow sustained transgene expression in myofibers with negligible anti-transgene IgG production. In this study, we screened individual and combinatorial miR-BS designs against 26 miRNAs that are abundantly expressed in APCs, but not in skeletal muscle. The highly immunogenic ovalbumin (OVA) transgene was used as a proxy for foreign antigens. In vitro screening in myoblasts, mouse DCs, and macrophages revealed that the combination of miR-142BS and miR-652-5pBS strongly mutes transgene expression in APCs but maintains high myoblast and myocyte expression. Importantly, rAAV1 vectors carrying this novel miR-142/652-5pBS cassette achieve higher transgene levels following intramuscular injections in mice than previous detargeting designs. The cassette strongly inhibits cytotoxic CTL activation and suppresses the Th17 response in vivo. Our approach, thus, advances the efficiency of miRNA-mediated detargeting to achieve synergistic reduction of transgene-specific immune responses and the development of safe and efficient delivery vehicles for gene therapy.Keywords
Funding Information
- National Institutes of Health (R01NS076991-01)
- National Institutes of Health (P01AI100263-01)
- National Institutes of Health (P01HL131471-02)
- National Institutes of Health (R01AI121135)
- National Institutes of Health (UG3HL147367-01)
- National Institutes of Health (R01HL097088)
- National Institutes of Health (U19AI149646-01)
This publication has 122 references indexed in Scilit:
- Long-term Safety and Efficacy Following Systemic Administration of a Self-complementary AAV Vector Encoding Human FIX Pseudotyped With Serotype 5 and 8 Capsid ProteinsMolecular Therapy, 2011
- MicroRNA-regulated, Systemically Delivered rAAV9: A Step Closer to CNS-restricted Transgene ExpressionMolecular Therapy, 2011
- Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liverGene Therapy, 2010
- Dystrophin Immunity in Duchenne's Muscular DystrophyNew England Journal of Medicine, 2010
- Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeysNature Medicine, 2009
- Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signalsProceedings of the National Academy of Sciences of the United States of America, 2009
- The interplay between the master transcription factor PU.1 and miR-424 regulates human monocyte/macrophage differentiationProceedings of the National Academy of Sciences of the United States of America, 2007
- Development, cytokine profile and function of human interleukin 17–producing helper T cellsNature Immunology, 2007
- A crucial role for interleukin (IL)-1 in the induction of IL-17–producing T cells that mediate autoimmune encephalomyelitisJournal of Experimental Medicine, 2006
- Two subsets of memory T lymphocytes with distinct homing potentials and effector functionsNature, 1999